戻る Agenda
Russia and the Eurasian Union – Regulatory Challenges and Opportunities
Session Chair(s)
Susanne Ausborn, PhD
Global Head International Regulatory Policy
Roche, Switzerland
The regulatory landscape in Russia and the “single market” of the Eurasian Union are rapidly evolving. Experts will share their perspectives on recent developments in the region and discuss the challenges we are facing with sometime very unique regulatory requirements. Examples for constructive dialogue between industry and regulators will be shared which is critical to bring and safe and efficacious drugs of high quality as fast as possible to the patients and maintain them on the market.
Speaker(s)
Regulatory Harmonisation within the Eurasian Union – Where Do We Stand?
Dmitriy Rozdestvensky, MD, PhD
Eurasian Economic Commission, Russian Federation
Head, Division for Coordination of Common Market for Drugs and Medical Devices F
Regulatory Harmonisation within the Eurasian Union – Where Do We Stand?
Sergey Glagolev
Federal Service for Supervision in Health Care (Rosdravnadzor), Russian Federation
Deputy Chief, Division for State Control of Medical Products
Establishing EEU Guidance - Driving Towards Regulatory Convergence - Industry Perspective
Elena Popova, DrMed
Association of International Pharmaceutical Manufacturers (AIPM), Russian Federation
Senior Director Regulatory Affairs & Healthcare Policy
Recent Developments and Challenges in Russia - Industry Perspective
Andrey Bulimov
Ironwood Pharmaceuticals, Switzerland
Head of International Regulatory Affairs